Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2

The poly(ADP-ribose) polymerase (PARP) family represents a new class of therapeutic targets with diverse potential disease indications. PARP1 and PARP2 inhibitors have been developed for breast and ovarian tumors manifesting double-stranded DNA-repair defects, whereas tankyrase 1 and 2 (TNKS1 and TN...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Wei, Lam, Robert, Voytyuk, Oleksandr, Romanov, Vladimir, Gordon, Roni, Gebremeskel, Simon, Vodsedalek, Jakub, Thompson, Christine, Beletskaya, Irina, Battaile, Kevin P., Pai, Emil F., Rottapel, Robert, Chirgadze, Nickolay Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union of Crystallography 2014
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188013/
https://www.ncbi.nlm.nih.gov/pubmed/25286857
http://dx.doi.org/10.1107/S1399004714017660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188013/
https://www.ncbi.nlm.nih.gov/pubmed/25286857
http://dx.doi.org/10.1107/S1399004714017660

Ejemplares similares